| Date Filed | Type | Description |
| 10/10/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/10/2023 |
8-K/A
| Quarterly results |
| 10/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/06/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/06/2023 |
8-K
| Other Events Interactive Data |
| 08/25/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/19/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 07/06/2023 |
4
| Fenton Mary Kay (CFO) has filed a Form 4 on Talaris Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 12,946 shares
@ $3.08, valued at
$39.9k
|
|
| 07/06/2023 |
4
| Requadt Scott (Former Chief Executive Officer) has filed a Form 4 on Talaris Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 11,786 shares
@ $3.08, valued at
$36.3k
|
|
| 07/06/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 5.5% stake in TALARIS THERAPEUTICS, INC. |
| 07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
4
| Ildstad Suzanne (Director) has filed a Form 4 on Talaris Therapeutics, Inc.|
Txns:
| Sold 75,001 shares
@ $2.3879, valued at
$179.1k
Sold 40,642 shares
@ $2.4795, valued at
$100.8k
Sold 25,419 shares
@ $2.4642, valued at
$62.6k
|
|
| 06/07/2023 |
4
| Ildstad Suzanne (Director) has filed a Form 4 on Talaris Therapeutics, Inc.|
Txns:
| Sold 7,841 shares
@ $2.5194, valued at
$19.8k
Sold 25,549 shares
@ $2.5283, valued at
$64.6k
|
|
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/02/2023 |
4
| Ildstad Suzanne (Director) has filed a Form 4 on Talaris Therapeutics, Inc.|
Txns:
| Sold 29 shares
@ $2.05, valued at
$59.5 |
|
| 02/23/2023 |
4
| Ildstad Suzanne (Director) has filed a Form 4 on Talaris Therapeutics, Inc.|
Txns:
| Sold 3,500 shares
@ $2.0529, valued at
$7.2k
|
|
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|